Recommendation of the President – Flutixon Nasal (Azelastini hydrochloridum + Fluticasoni propionas)
On 23 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 204/2025 on the reimbursement of the medicinal product Flutixon Nasal (Azelastini hydrochloridum + Fluticasoni propionas) for the indication: relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis, if the use of other intranasal products containing only an antihistamine or glucocorticosteroid is considered insufficient.